NASDAQ: URGN - UroGen Pharma Ltd.

Yield per half year: -15.87%
Dividend yield: 0.00%
Sector: Healthcare

Share chart UroGen Pharma Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer.

more details
It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-05-04
ISIN IL0011407140
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.urogen.com
Цена ао 11.52
Change price per day: 0% (10.6)
Change price per week: +9.73% (9.66)
Change price per month: -4.25% (11.07)
Change price per 3 month: +6.75% (9.93)
Change price per half year: -15.87% (12.6)
Change price per year: -26.85% (14.49)
Change price per 3 year: +34.18% (7.9)
Change price per 5 year: -25.72% (14.27)
Change price per year to date: -14.1% (12.34)
All parameters

Underestimation

Title Value Grade
P/S 4.99 3
P/BV -51.24 0
P/E 0 0
EV/EBITDA -4.16 0
Total: 4.13

Efficiency

Title Value Grade
ROA, % -54.68 0
ROE, % 342.83 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.27 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 666.08 10
Yield Ebitda, % -23.61 0
Yield EPS, % -49.85 0
Total: 2
More

Institutions Volume Share, %
Great Point Partners LLC 2620545 8.49
Menora Mivtachim Holdings Ltd. 2303031 7.46
RA Capital Management, L.P. 1483697 4.81
Blackrock Inc. 1197647 3.88
Credit Suisse Ag/ 1060000 3.43
Harel Insurance Investments & Financial Services Ltd. 870194 2.82
RTW Investments LP 857464 2.78
Migdal Insurance & Financial Holdings Ltd. 648302 2.1
SILVERARC CAPITAL MANAGEMENT, LLC 508883 1.65
Wildcat Capital Management, LLC 495606 1.61

ETF Share, % Profitability for 1 year, % Dividends, %
Future Tech ETF 0.05533 426.34 0.8416
Principal Healthcare Innovators ETF 0.05533 618.5 0.8416



Head Job title Payment Year of birth
Ms. Elizabeth A. Barrett President, CEO & Director 1.12M 1962 (63 years)
Mr. Dong Kim Chief Financial Officer 546.68k 1977 (48 years)
Mr. Jason Drew Smith General Counsel, Chief Compliance Officer & Corporate Secretary 717.58k 1972 (53 years)
Vincent I. Perrone Senior Director of Investor Relations N/A
Mr. Bryon Wornson Executive Vice President of Talent, Advocacy & Communications N/A
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 579.5k 1958 (67 years)
Mr. James Ottinger R.ph. Executive Vice President of Regulatory Affairs & Quality N/A
Dr. Marina Konorty Ph.D. Executive Vice President of Research & Development and Technical Operations
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. Chief Business Officer 1965 (60 years)
Mr. Michael J. Louie M.D., M.P.H., M.Sc. Senior Vice President of Medical Affairs & Clinical Development

Address: United States, Princeton. NJ, 400 Alexander Park - open in Google maps, open in Yandex maps
Website: https://www.urogen.com